DA
DYN icon

Denali Advisors’s Dyne Therapeutics DYN Stock Holding History

Denali Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,700
Closed -$30.4K – 490
2023
Q2 		$30.4K Hold
2,700
– – 0.01% 315
2023
Q1 		$31.1K Hold
2,700
– – 0.01% 262
2022
Q4 		$31.3K Sell
2,700
-2,100
-44% -$24.3K 0.01% 274
2022
Q3 		$61K Buy
+4,800
New +$55K 0.03% 196

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Denali Advisors's DYN Position: Q3 2023 in Review

Denali Advisors sold out of Dyne Therapeutics (DYN) in Q3 2023, closing a stake of 2,700 shares — an estimated $30.4K sold.

Denali Advisors first reported a position in DYN in Q3 2022 and held it in 4 quarters. The position peaked at $61K in Q3 2022. 114 funds tracked by Wall St. Rank hold DYN as of Q3 2023.

  • Denali Advisors reported no remaining Dyne Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Denali Advisors sold 2,700 Dyne Therapeutics shares in Q3 2023, an estimated $30.4K.
  • Denali Advisors first reported a position in Dyne Therapeutics in Q3 2022 and held it in 4 quarters.
  • Denali Advisors's Dyne Therapeutics position peaked at $61K in Q3 2022.
  • 114 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.